https://www.selleckchem.com/pr....oducts/AZD2281(Olapa
The docking study of the most potent compound against VEGFR-2 with the best-scored conformations displayed a binding affinity (-9.5 kcal/mol) comparable with the drug sunitinib (-9.9 kcal/mol) and exhibited that tighter interactions at the active adenosine triphosphate site might be responsible for anticancer potency. The purpose of this study is to analyze the US FDA Adverse Event Reporting System (FAERS) to identify adverse cardiac events of hydroxychloroquine in older adults. A case/non-case method was used to determine adv
Like
Comment
Share
